DISEASE INDICATIONS: Achondroplasia

MANUFACTURER: BioMarin Europe Ltd

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Voxzogo is a prescription medication that is used to treat achondroplasia in children aged 2 to 18, a genetic disorder that causes short stature and bone deformities. Developed by BioMarin Pharmaceutical, Voxzogo stimulates bone growth by binding to the CNP receptor, which is involved in regulating bone growth.